Application of CGE in cell and gene therapy by Kerstin Pohl | Mar 12, 2025 | Biopharma, BioPhase 8800 system, BlogsIn a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
The whys behind the dos and don’ts of oligonucleotide analysis by Kerstin Pohl | Feb 1, 2025 | Biopharma, Blogs, PharmaWe know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.
Tips and tricks from our application experts: AAV analysis with CE by Peter Holper | Jan 24, 2025 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemPeter Holper, Staff Applications Scientist at SCIEX, US, shares his tips and tricks on AAV analysis using CE with the BioPhase 8800 system and the PA 800 Plus system.
Plasmid manufacturing: Setting up your CGT programs for success by Kerstin Pohl | Nov 15, 2024 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemPlasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in plasmid manufacturing, provided insights into the process and an outlook on the future.
Celebrating customer experience: Insights from SCIEX leaders by Philip Taylor | Oct 1, 2024 | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, TechnologyIntroduction Customer Experience Day (CX Day) is a special occasion for SCIEX, celebrated every first Tuesday in October. It’s a day dedicated to recognizing the incredible value of our customers and the relentless dedication of our associates who strive to make...
Your success and voice go a long way! by Philip Taylor | Sep 25, 2024 | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, TechnologyAt the heart of everything we do is ensuring that your workflows and team are empowered to achieve optimal results with your SCIEX instruments, software, consumables, and services. Every interaction with SCIEX is designed to support your success through the dedication...
Pure and simple: Understanding LNP analytics for better mRNA-based drugs by Kerstin Pohl | Jul 3, 2024 | Biopharma, Blogs, ZenoTOF 7600 systemA few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of N-oxide impurities. The ionizable lipids used in LNPs are especially susceptible to forming N-oxide impurities.
Discover high-quality mRNA integrity and purity assessments by Kerstin Pohl | May 22, 2024 | Biopharma, BioPhase 8800 system, BlogsLipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA (mRNA) products, most notably used for production of vaccines against the recent SARS-CoV-2 pandemic.
Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | May 13, 2024 | Biopharma, BioPhase 8800 system, BlogsIn a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products.
A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics by Kerstin Pohl | Apr 29, 2024 | Biopharma, Blogs, Pharma, QTOF, QTRAP / Triple Quad, ZenoTOF 7600 systemIn 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.